Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18095213 | 0.87 | KDM4E (0.39) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL20798434 | 0.83 | CA1 (0.49) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL31385433 | 0.81 | MAPT (0.50) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL31385413 | 0.81 | RORC (0.44) | KDM4ESMN1; SMN2HSD17B10ALDH1A1MAPT | |
| SCHEMBL31356459 | 0.81 | NOTUM (0.44) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL25721981 | 0.79 | TDP1 (0.52) | KDM4ESMN1; SMN2HSD17B10ALDH1A1MAPT | |
| SCHEMBL14175211 | 0.79 | TDP1 (0.52) | KDM4ESMN1; SMN2HSD17B10ALDH1A1MAPT | |
| SCHEMBL2967855 | 0.79 | CA12 (0.45) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 | |
| SCHEMBL2968528 | 0.78 | ALDH1A1 (0.53) | KDM4ESMN1; SMN2HSD17B10ALDH1A1MAPT | |
| SCHEMBL4576366 | 0.78 | CYP2C9 (0.41) | KDM4ESMN1; SMN2HSD17B10CYP2C9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013797-B1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE LTD (KY) | 2018-01-03 | — | — | EP | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-9670231-B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | BEIGENE, LTD. (KY) | 2017-06-06 | — | — | US | disclosed |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (KY) | 2016-06-09 | — | — | US | disclosed |
| EP-3013797-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014206344-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BEIGENE, LTD. (GB) | 2014-12-31 | — | — | WO | disclosed |
| US-8088802-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| EP-1612208-B1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7629369-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-12-08 | — | — | US | disclosed |
| US-7335776-B2 | Remedies for depression containing EP1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-26 | — | — | US | disclosed |
| US-7235667-B2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-06-26 | — | — | US | disclosed |
| EP-1369419-B1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. | 2006-02-09 | — | — | US | disclosed |
| EP-1612208-A2 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-09 | — | — | US | disclosed |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1369419-A1 | N-PHENYLARYLSULFONAMIDE COMPOUND, DRUG CONTAINING THE COMPOUND AS ACTIVE INGREDIENT, INTERMEDIATE FOR THE COMPOUND, AND PROCESSES FOR PRODUCING THE SAME | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
| EP-1369129-A1 | REMEDIES FOR DEPRESSION CONTAINING EP1 ANTAGONIST AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030713-A1 | N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for its preparation | PTGER1, PTGER2, PTGES | KDM4E 2131/4885SMN1; SMN2 2389/4885HSD17B10 3424/4885 |
| US-20160159820-A1 | FUSED TRICYCLIC AMIDE COMPOUNDS AS MULTIPLE KINASE INHIBITORS | BRAF, EGFR, ERBB2 | KDM4E 1679/4885SMN1; SMN2 4663/4885HSD17B10 3079/4885 |
| US-20050124672-A1 | N-phenylarylsulfonamide compound drug containing the compound as active ingredient intermediate for the compound and processes for producing the same | PTGER1, PTGER2, PTGES | KDM4E 2106/4885SMN1; SMN2 2475/4885HSD17B10 3067/4885 |
| US-20040082653-A1 | Remedies for depression containing ep1 antagonist as the active ingredient | PTGER1, PTGER2, PTGS1 | KDM4E 4138/4885SMN1; SMN2 3875/4885HSD17B10 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.